Gadavist

Gadavist is a brand name of gadobutrol, approved by the FDA in the following formulation(s):

GADAVIST (gadobutrol - solution; intravenous)

• 
  Manufacturer: BAYER HLTHCARE
  
  Approval date: March 14, 2011
  
  Strength(s): 18.1416GM/30ML (604.72MG/ML) ^[RLD], 39.3068GM/65ML (604.72MG/ML) ^[RLD], 4.5354GM/7.5ML (604.72MG/ML) ^[RLD], 6.0472GM/10ML (604.72MG/ML) ^[RLD], 9.0708GM/15ML (604.72MG/ML) ^[RLD]

Has a generic version of Gadavist been approved?

No. There is currently no therapeutically equivalent version of Gadavist available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Gadavist. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them
  Patent 5,980,864
  Issued: November 9, 1999
  Inventor(s): Platzek; Johannes & Gries; Heinz & Weinmann; Hanns-Joachim & Schuhmann-Giampieri; Gabriele & Press; Wolf-Rudiger
  Assignee(s): Schering Aktiengellsellschaft
  1,4,7,10-Tetraazacyclodedecane butyltriols of general formula I.sub.A ##STR1## in which R.sup.1 means hydrogen or a metal ion equivalent independent of one another and R.sup.2 means a butyltriol radical as well as their salts with organic or inorganic bases or amino acids are valuable pharmaceutical agents.
  
  Patent expiration dates:
  
  
  • November 9, 2016
    
    ✓ 
    Patent use: CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • March 14, 2016 - NEW CHEMICAL ENTITY
  
  

See also...

• Gadavist Consumer Information (Drugs.com)
• Gadavist Advanced Consumer Information (Micromedex)
• Gadobutrol Intravenous Advanced Consumer Information (Micromedex)